首页 > 最新文献

Experimental and Molecular Medicine最新文献

英文 中文
CMTM6 mediates the Warburg effect and promotes the liver metastasis of colorectal cancer CMTM6 介导沃伯格效应并促进结直肠癌的肝转移。
IF 9.5 2区 医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-09-02 DOI: 10.1038/s12276-024-01303-1
Aurpita Shaha, Yuanguo Wang, Xianghu Wang, Dong Wang, David Guinovart, Bin Liu, Ningling Kang
Liver metastasis of colorectal cancer (CRC) is a leading cause of death among cancer patients. The overexpression of glucose transporter 1 (Glut1) and enhanced glucose uptake that are associated with the Warburg effect are frequently observed in CRC liver metastases, but the underlying mechanisms remain poorly understood. CKLF-like MARVEL transmembrane domain-containing protein 6 (CMTM6) regulates the intracellular trafficking of programmed death-ligand-1 (PD-L1); therefore, we investigated whether CMTM6 regulates Glut1 trafficking and the Warburg effect in CRC cells. We found that knocking down of CMTM6 by shRNA induced the lysosomal degradation of Glut1, decreased glucose uptake and glycolysis in CRC cells, and suppressed subcutaneous CRC growth in nude mice and liver metastasis in C57BL/6 mice. Mechanistically, CMTM6 forms a complex with Glut1 and Rab11 in the endosomes of CRC cells, and this complex is required for the Rab11-dependent transport of Glut1 to the plasma membrane and for the protection of Glut1 from lysosomal degradation. Multiomics revealed global transcriptomic changes in CMTM6-knockdown CRC cells that affected the transcriptomes of adjacent cancer-associated fibroblasts from CRC liver metastases. As a result of these transcriptomic changes, CMTM6-knockdown CRC cells exhibited a defect in the G2-to-M phase transition, reduced secretion of 60 cytokines/chemokines, and inability to recruit cancer-associated fibroblasts to support an immunosuppressive CRC liver metastasis microenvironment. Analysis of TCGA data confirmed that CMTM6 expression was increased in CRC patients and that elevated CMTM6 expression was associated with worse patient survival. Together, our data suggest that CMTM6 plays multiple roles in regulating the Warburg effect, transcriptome, and liver metastasis of CRC. Liver metastasis in colorectal cancer patients increases death rates, with current treatments often inadequate due to a lack of understanding of the underlying processes. This study explores how CRC cells change their metabolism to survive in the liver, focusing on the Warburg effect, where cancer cells use glycolysis preferentially. It focuses on the role of a protein called CMTM6 in this metabolic change. The researchers performed experiments on human and mouse CRC cells and used both in vitro and in vivo models, including mice with and without immune systems, to study the effects of CMTM6 on CRC growth and liver metastasis. The results showed reducing CMTM6 levels led to decreased glycolysis of CRC cells, CRC tumor growth and liver metastasis in mice. Future studies could lead to more effective treatments for CRC patients with liver metastases. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.
结肠直肠癌(CRC)的肝转移是导致癌症患者死亡的主要原因。在 CRC 肝转移灶中经常观察到葡萄糖转运体 1(Glut1)的过表达和与沃伯格效应相关的葡萄糖摄取增强,但对其潜在机制仍知之甚少。CKLF-like MARVEL跨膜结构域含蛋白6(CMTM6)调控程序性死亡配体-1(PD-L1)的胞内转运;因此,我们研究了CMTM6是否调控CRC细胞中Glut1的转运和沃伯格效应。我们发现,通过 shRNA 敲除 CMTM6 可诱导 Glut1 的溶酶体降解,降低 CRC 细胞的葡萄糖摄取和糖酵解,抑制裸鼠皮下 CRC 生长和 C57BL/6 小鼠的肝转移。从机理上讲,CMTM6与CRC细胞内体中的Glut1和Rab11形成复合物,该复合物是Rab11依赖性转运Glut1至质膜和保护Glut1免于溶酶体降解所必需的。多组学揭示了CMTM6敲除的CRC细胞中的全局转录组变化,这些变化影响了来自CRC肝转移灶的邻近癌相关成纤维细胞的转录组。由于这些转录组变化,CMTM6-敲除的 CRC 细胞表现出 G2 到 M 期转变缺陷、60 种细胞因子/趋化因子分泌减少以及无法招募癌相关成纤维细胞以支持免疫抑制性 CRC 肝转移微环境。对 TCGA 数据的分析证实,CMTM6 在 CRC 患者中的表达增加,而 CMTM6 表达的升高与患者生存率的降低有关。总之,我们的数据表明,CMTM6 在调控 CRC 的沃伯格效应、转录组和肝脏转移方面发挥着多重作用。
{"title":"CMTM6 mediates the Warburg effect and promotes the liver metastasis of colorectal cancer","authors":"Aurpita Shaha, Yuanguo Wang, Xianghu Wang, Dong Wang, David Guinovart, Bin Liu, Ningling Kang","doi":"10.1038/s12276-024-01303-1","DOIUrl":"10.1038/s12276-024-01303-1","url":null,"abstract":"Liver metastasis of colorectal cancer (CRC) is a leading cause of death among cancer patients. The overexpression of glucose transporter 1 (Glut1) and enhanced glucose uptake that are associated with the Warburg effect are frequently observed in CRC liver metastases, but the underlying mechanisms remain poorly understood. CKLF-like MARVEL transmembrane domain-containing protein 6 (CMTM6) regulates the intracellular trafficking of programmed death-ligand-1 (PD-L1); therefore, we investigated whether CMTM6 regulates Glut1 trafficking and the Warburg effect in CRC cells. We found that knocking down of CMTM6 by shRNA induced the lysosomal degradation of Glut1, decreased glucose uptake and glycolysis in CRC cells, and suppressed subcutaneous CRC growth in nude mice and liver metastasis in C57BL/6 mice. Mechanistically, CMTM6 forms a complex with Glut1 and Rab11 in the endosomes of CRC cells, and this complex is required for the Rab11-dependent transport of Glut1 to the plasma membrane and for the protection of Glut1 from lysosomal degradation. Multiomics revealed global transcriptomic changes in CMTM6-knockdown CRC cells that affected the transcriptomes of adjacent cancer-associated fibroblasts from CRC liver metastases. As a result of these transcriptomic changes, CMTM6-knockdown CRC cells exhibited a defect in the G2-to-M phase transition, reduced secretion of 60 cytokines/chemokines, and inability to recruit cancer-associated fibroblasts to support an immunosuppressive CRC liver metastasis microenvironment. Analysis of TCGA data confirmed that CMTM6 expression was increased in CRC patients and that elevated CMTM6 expression was associated with worse patient survival. Together, our data suggest that CMTM6 plays multiple roles in regulating the Warburg effect, transcriptome, and liver metastasis of CRC. Liver metastasis in colorectal cancer patients increases death rates, with current treatments often inadequate due to a lack of understanding of the underlying processes. This study explores how CRC cells change their metabolism to survive in the liver, focusing on the Warburg effect, where cancer cells use glycolysis preferentially. It focuses on the role of a protein called CMTM6 in this metabolic change. The researchers performed experiments on human and mouse CRC cells and used both in vitro and in vivo models, including mice with and without immune systems, to study the effects of CMTM6 on CRC growth and liver metastasis. The results showed reducing CMTM6 levels led to decreased glycolysis of CRC cells, CRC tumor growth and liver metastasis in mice. Future studies could lead to more effective treatments for CRC patients with liver metastases. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.","PeriodicalId":50466,"journal":{"name":"Experimental and Molecular Medicine","volume":"56 9","pages":"2002-2015"},"PeriodicalIF":9.5,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s12276-024-01303-1.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142114386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mesocorticolimbic circuit mechanisms of social dominance behavior 社会支配行为的中皮质边缘回路机制
IF 9.5 2区 医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-09-02 DOI: 10.1038/s12276-024-01299-8
Tae-Yong Choi, Sejin Jeong, Ja Wook Koo
Social animals, including rodents, primates, and humans, partake in competition for finite resources, thereby establishing social hierarchies wherein an individual’s social standing influences diverse behaviors. Understanding the neurobiological underpinnings of social dominance is imperative, given its ramifications for health, survival, and reproduction. Social dominance behavior comprises several facets, including social recognition, social decision-making, and actions, indicating the concerted involvement of multiple brain regions in orchestrating this behavior. While extensive research has been dedicated to elucidating the neurobiology of social interaction, recent studies have increasingly delved into adverse social behaviors such as social competition and hierarchy. This review focuses on the latest advancements in comprehending the mechanisms of the mesocorticolimbic circuit governing social dominance, with a specific focus on rodent studies, elucidating the intricate dynamics of social hierarchies and their implications for individual well-being and adaptation. In the animal world, the fight for food and mates often results in social rankings, with dominant animals getting better access to resources. This review explores the brain biology of social dominance, focusing on specific brain circuits in rodents. Using behavioral tests, they’ve started to understand how different brain areas and their connections affect social ranking among animals. The study combines results from many experiments to better understand how social dominance is wired in the brain. The results highlight the complexity of social dominance, showing it as a trait influenced by multiple brain areas and their interactions. They conclude that understanding these brain processes is key for understanding the wider implications of social behavior in health and disease. Their work improves our understanding of the biological basis of social hierarchies, suggesting potential targets for treating social behavior disorders. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.
包括啮齿类动物、灵长类动物和人类在内的社会性动物都参与了对有限资源的竞争,从而建立了社会等级制度,个体的社会地位影响着各种行为。考虑到社会优势对健康、生存和繁殖的影响,了解社会优势的神经生物学基础势在必行。社会支配行为由多个方面组成,包括社会识别、社会决策和行动,这表明有多个脑区共同参与了这种行为的协调。虽然大量研究致力于阐明社会互动的神经生物学,但最近的研究越来越多地深入到不利的社会行为,如社会竞争和等级制度。本综述将重点介绍在理解支配社会支配地位的皮质中脑边缘回路机制方面取得的最新进展,尤其侧重于啮齿动物研究,阐明社会等级制度的复杂动态及其对个体福祉和适应的影响。
{"title":"Mesocorticolimbic circuit mechanisms of social dominance behavior","authors":"Tae-Yong Choi, Sejin Jeong, Ja Wook Koo","doi":"10.1038/s12276-024-01299-8","DOIUrl":"10.1038/s12276-024-01299-8","url":null,"abstract":"Social animals, including rodents, primates, and humans, partake in competition for finite resources, thereby establishing social hierarchies wherein an individual’s social standing influences diverse behaviors. Understanding the neurobiological underpinnings of social dominance is imperative, given its ramifications for health, survival, and reproduction. Social dominance behavior comprises several facets, including social recognition, social decision-making, and actions, indicating the concerted involvement of multiple brain regions in orchestrating this behavior. While extensive research has been dedicated to elucidating the neurobiology of social interaction, recent studies have increasingly delved into adverse social behaviors such as social competition and hierarchy. This review focuses on the latest advancements in comprehending the mechanisms of the mesocorticolimbic circuit governing social dominance, with a specific focus on rodent studies, elucidating the intricate dynamics of social hierarchies and their implications for individual well-being and adaptation. In the animal world, the fight for food and mates often results in social rankings, with dominant animals getting better access to resources. This review explores the brain biology of social dominance, focusing on specific brain circuits in rodents. Using behavioral tests, they’ve started to understand how different brain areas and their connections affect social ranking among animals. The study combines results from many experiments to better understand how social dominance is wired in the brain. The results highlight the complexity of social dominance, showing it as a trait influenced by multiple brain areas and their interactions. They conclude that understanding these brain processes is key for understanding the wider implications of social behavior in health and disease. Their work improves our understanding of the biological basis of social hierarchies, suggesting potential targets for treating social behavior disorders. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.","PeriodicalId":50466,"journal":{"name":"Experimental and Molecular Medicine","volume":"56 9","pages":"1889-1899"},"PeriodicalIF":9.5,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s12276-024-01299-8.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142114390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Distinct binding conformations of epinephrine with α- and β-adrenergic receptors 肾上腺素与 α 和 β 肾上腺素能受体的不同结合构象。
IF 9.5 2区 医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-09-02 DOI: 10.1038/s12276-024-01296-x
Jian-Shu Lou, Minfei Su, Jinan Wang, Hung Nguyen Do, Yinglong Miao, Xin-Yun Huang
Agonists targeting α2-adrenergic receptors (ARs) are used to treat diverse conditions, including hypertension, attention-deficit/hyperactivity disorder, pain, panic disorders, opioid and alcohol withdrawal symptoms, and cigarette cravings. These receptors transduce signals through heterotrimeric Gi proteins. Here, we elucidated cryo-EM structures that depict α2A-AR in complex with Gi proteins, along with the endogenous agonist epinephrine or the synthetic agonist dexmedetomidine. Molecular dynamics simulations and functional studies reinforce the results of the structural revelations. Our investigation revealed that epinephrine exhibits different conformations when engaging with α-ARs and β-ARs. Furthermore, α2A-AR and β1-AR (primarily coupled to Gs, with secondary associations to Gi) were compared and found to exhibit different interactions with Gi proteins. Notably, the stability of the epinephrine–α2A-AR–Gi complex is greater than that of the dexmedetomidine–α2A-AR–Gi complex. These findings substantiate and improve our knowledge on the intricate signaling mechanisms orchestrated by ARs and concurrently shed light on the regulation of α-ARs and β-ARs by epinephrine. Our bodies have a system, the sympathetic nervous system, that uses certain chemicals to control heart rate, blood pressure, etc. These chemicals, epinephrine and norepinephrine, work by activating proteins known as adrenergic receptors. Understanding these receptors could help treat diseases like high blood pressure and ADHD. This study used a method called cryo-electron microscopy to see how epinephrine interacts with these receptors. It compared how epinephrine and a similar drug, dexmedetomidine, interact with the receptors. The study found that epinephrine binds to the α and β types of the receptors differently, which could explain their different effects. This helps us understand how drugs that mimic or block epinephrine can treat diseases. This could lead to new, more effective drugs. Future research may use these findings to design better treatments for heart diseases and other conditions. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.
以α2肾上腺素能受体(ARs)为靶点的激动剂可用于治疗多种疾病,包括高血压、注意力缺陷/多动障碍、疼痛、恐慌症、阿片类药物和酒精戒断症状以及烟瘾。这些受体通过异三聚 Gi 蛋白传递信号。在这里,我们阐明了描述α2A-AR与Gi蛋白以及内源性激动剂肾上腺素或合成激动剂右美托咪定复合物的低温电子显微镜结构。分子动力学模拟和功能研究加强了结构揭示的结果。我们的研究发现,肾上腺素在与α-ARs 和 β-ARs 结合时呈现出不同的构象。此外,我们还比较了α2A-AR 和 β1-AR(主要与 Gs 耦合,次要与 Gi 关联),发现它们与 Gi 蛋白的相互作用各不相同。值得注意的是,肾上腺素-α2A-AR-Gi 复合物的稳定性高于右美托咪定-α2A-AR-Gi 复合物。这些发现证实并提高了我们对 ARs 错综复杂的信号转导机制的认识,同时也揭示了肾上腺素对 α-ARs 和 β-ARs 的调控作用。
{"title":"Distinct binding conformations of epinephrine with α- and β-adrenergic receptors","authors":"Jian-Shu Lou, Minfei Su, Jinan Wang, Hung Nguyen Do, Yinglong Miao, Xin-Yun Huang","doi":"10.1038/s12276-024-01296-x","DOIUrl":"10.1038/s12276-024-01296-x","url":null,"abstract":"Agonists targeting α2-adrenergic receptors (ARs) are used to treat diverse conditions, including hypertension, attention-deficit/hyperactivity disorder, pain, panic disorders, opioid and alcohol withdrawal symptoms, and cigarette cravings. These receptors transduce signals through heterotrimeric Gi proteins. Here, we elucidated cryo-EM structures that depict α2A-AR in complex with Gi proteins, along with the endogenous agonist epinephrine or the synthetic agonist dexmedetomidine. Molecular dynamics simulations and functional studies reinforce the results of the structural revelations. Our investigation revealed that epinephrine exhibits different conformations when engaging with α-ARs and β-ARs. Furthermore, α2A-AR and β1-AR (primarily coupled to Gs, with secondary associations to Gi) were compared and found to exhibit different interactions with Gi proteins. Notably, the stability of the epinephrine–α2A-AR–Gi complex is greater than that of the dexmedetomidine–α2A-AR–Gi complex. These findings substantiate and improve our knowledge on the intricate signaling mechanisms orchestrated by ARs and concurrently shed light on the regulation of α-ARs and β-ARs by epinephrine. Our bodies have a system, the sympathetic nervous system, that uses certain chemicals to control heart rate, blood pressure, etc. These chemicals, epinephrine and norepinephrine, work by activating proteins known as adrenergic receptors. Understanding these receptors could help treat diseases like high blood pressure and ADHD. This study used a method called cryo-electron microscopy to see how epinephrine interacts with these receptors. It compared how epinephrine and a similar drug, dexmedetomidine, interact with the receptors. The study found that epinephrine binds to the α and β types of the receptors differently, which could explain their different effects. This helps us understand how drugs that mimic or block epinephrine can treat diseases. This could lead to new, more effective drugs. Future research may use these findings to design better treatments for heart diseases and other conditions. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.","PeriodicalId":50466,"journal":{"name":"Experimental and Molecular Medicine","volume":"56 9","pages":"1952-1966"},"PeriodicalIF":9.5,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s12276-024-01296-x.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142114387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Author Correction: Tonic excitation by astrocytic GABA causes neuropathic pain by augmenting neuronal activity and glucose metabolism 作者更正:星形胶质细胞 GABA 的强直性兴奋通过增强神经元活动和葡萄糖代谢导致神经病理性疼痛。
IF 9.5 2区 医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-08-30 DOI: 10.1038/s12276-024-01306-y
Yeon Ha Ju, Jongwook Cho, Ji-Young Park, Hyunjin Kim, Eun-Bin Hong, Ki Duk Park, C. Justin Lee, Euiheon Chung, Hyoung-Ihl Kim, Min-Ho Nam
{"title":"Author Correction: Tonic excitation by astrocytic GABA causes neuropathic pain by augmenting neuronal activity and glucose metabolism","authors":"Yeon Ha Ju, Jongwook Cho, Ji-Young Park, Hyunjin Kim, Eun-Bin Hong, Ki Duk Park, C. Justin Lee, Euiheon Chung, Hyoung-Ihl Kim, Min-Ho Nam","doi":"10.1038/s12276-024-01306-y","DOIUrl":"10.1038/s12276-024-01306-y","url":null,"abstract":"","PeriodicalId":50466,"journal":{"name":"Experimental and Molecular Medicine","volume":"56 8","pages":"1887-1887"},"PeriodicalIF":9.5,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s12276-024-01306-y.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142114384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Altered lipid metabolism promoting cardiac fibrosis is mediated by CD34+ cell-derived FABP4+ fibroblasts CD34+细胞衍生的FABP4+成纤维细胞介导了促进心脏纤维化的脂质代谢改变。
IF 9.5 2区 医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-08-29 DOI: 10.1038/s12276-024-01309-9
Luping Du, Xuyang Wang, Yan Guo, Tingting Tao, Hong Wu, Xiaodong Xu, Bohuan Zhang, Ting Chen, Qingbo Xu, Xiaogang Guo
Hyperlipidemia and hypertension might play a role in cardiac fibrosis, in which a heterogeneous population of fibroblasts seems important. However, it is unknown whether CD34+ progenitor cells are involved in the pathogenesis of heart fibrosis. This study aimed to explore the mechanism of CD34+ cell differentiation in cardiac fibrosis during hyperlipidemia. Through the analysis of transcriptomes from 50,870 single cells extracted from mouse hearts and 76,851 single cells from human hearts, we have effectively demonstrated the evolving cellular landscape throughout cardiac fibrosis. Disturbances in lipid metabolism can accelerate the development of fibrosis. Through the integration of bone marrow transplantation models and lineage tracing, our study showed that hyperlipidemia can expedite the differentiation of non-bone marrow-derived CD34+ cells into fibroblasts, particularly FABP4+ fibroblasts, in response to angiotensin II. Interestingly, the partial depletion of CD34+ cells led to a notable reduction in triglycerides in the heart, mitigated fibrosis, and improved cardiac function. Furthermore, immunostaining of human heart tissue revealed colocalization of CD34+ cells and fibroblasts. Mechanistically, our investigation of single-cell RNA sequencing data through pseudotime analysis combined with in vitro cellular studies revealed the crucial role of the PPARγ/Akt/Gsk3β pathway in orchestrating the differentiation of CD34+ cells into FABP4+ fibroblasts. Through our study, we generated valuable insights into the cellular landscape of CD34+ cell-derived cells in the hypertrophic heart with hyperlipidemia, indicating that the differentiation of non-bone marrow-derived CD34+ cells into FABP4+ fibroblasts during this process accelerates lipid accumulation and promotes heart failure via the PPARγ/Akt/Gsk3β pathway. Cardiac fibrosis, a condition leading to heart failure, is caused by the activation of cardiac fibroblasts. These cells are influenced by various factors, including disorders in lipid metabolism. The role of lipid metabolism in cardiac fibrosis, particularly under conditions like hyperlipidemia and hypertension, is not fully understood. This study investigates how lipid metabolism disorders affect cardiac fibrosis and the role of certain cells in this process. The research uses human heart samples and mouse models, including a specific type of genetically modified mouse with induced hypertension. The study reveals that lipid metabolism disorders significantly contribute to cardiac fibrosis by promoting the transformation of CD34+ cells into FABP4+ fibroblasts, worsening heart fibrosis. The findings suggest potential new treatments for cardiac fibrosis. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.
高脂血症和高血压可能在心脏纤维化中起作用,其中异质性成纤维细胞群似乎很重要。然而,CD34+祖细胞是否参与了心脏纤维化的发病机制尚不清楚。本研究旨在探索CD34+细胞在高脂血症期间心脏纤维化中的分化机制。通过分析从小鼠心脏提取的50,870个单细胞和从人类心脏提取的76,851个单细胞的转录组,我们有效地展示了整个心脏纤维化过程中不断演变的细胞景观。脂质代谢紊乱会加速纤维化的发展。通过整合骨髓移植模型和系谱追踪,我们的研究表明,高脂血症可加速非骨髓来源的CD34+细胞在血管紧张素II作用下分化为成纤维细胞,尤其是FABP4+成纤维细胞。有趣的是,CD34+细胞的部分消耗导致心脏中甘油三酯明显减少,纤维化减轻,心脏功能得到改善。此外,人体心脏组织的免疫染色显示了 CD34+ 细胞和成纤维细胞的共定位。从机理上讲,我们通过伪时间分析对单细胞 RNA 测序数据进行了研究,并结合体外细胞研究揭示了 PPARγ/Akt/Gsk3β 通路在协调 CD34+ 细胞向 FABP4+ 成纤维细胞分化过程中的关键作用。通过我们的研究,我们对高脂血症肥厚型心脏中CD34+细胞衍生细胞的细胞景观有了宝贵的认识,表明在此过程中,非骨髓衍生的CD34+细胞分化成FABP4+成纤维细胞,通过PPARγ/Akt/Gsk3β途径加速脂质积累并促进心力衰竭。
{"title":"Altered lipid metabolism promoting cardiac fibrosis is mediated by CD34+ cell-derived FABP4+ fibroblasts","authors":"Luping Du, Xuyang Wang, Yan Guo, Tingting Tao, Hong Wu, Xiaodong Xu, Bohuan Zhang, Ting Chen, Qingbo Xu, Xiaogang Guo","doi":"10.1038/s12276-024-01309-9","DOIUrl":"10.1038/s12276-024-01309-9","url":null,"abstract":"Hyperlipidemia and hypertension might play a role in cardiac fibrosis, in which a heterogeneous population of fibroblasts seems important. However, it is unknown whether CD34+ progenitor cells are involved in the pathogenesis of heart fibrosis. This study aimed to explore the mechanism of CD34+ cell differentiation in cardiac fibrosis during hyperlipidemia. Through the analysis of transcriptomes from 50,870 single cells extracted from mouse hearts and 76,851 single cells from human hearts, we have effectively demonstrated the evolving cellular landscape throughout cardiac fibrosis. Disturbances in lipid metabolism can accelerate the development of fibrosis. Through the integration of bone marrow transplantation models and lineage tracing, our study showed that hyperlipidemia can expedite the differentiation of non-bone marrow-derived CD34+ cells into fibroblasts, particularly FABP4+ fibroblasts, in response to angiotensin II. Interestingly, the partial depletion of CD34+ cells led to a notable reduction in triglycerides in the heart, mitigated fibrosis, and improved cardiac function. Furthermore, immunostaining of human heart tissue revealed colocalization of CD34+ cells and fibroblasts. Mechanistically, our investigation of single-cell RNA sequencing data through pseudotime analysis combined with in vitro cellular studies revealed the crucial role of the PPARγ/Akt/Gsk3β pathway in orchestrating the differentiation of CD34+ cells into FABP4+ fibroblasts. Through our study, we generated valuable insights into the cellular landscape of CD34+ cell-derived cells in the hypertrophic heart with hyperlipidemia, indicating that the differentiation of non-bone marrow-derived CD34+ cells into FABP4+ fibroblasts during this process accelerates lipid accumulation and promotes heart failure via the PPARγ/Akt/Gsk3β pathway. Cardiac fibrosis, a condition leading to heart failure, is caused by the activation of cardiac fibroblasts. These cells are influenced by various factors, including disorders in lipid metabolism. The role of lipid metabolism in cardiac fibrosis, particularly under conditions like hyperlipidemia and hypertension, is not fully understood. This study investigates how lipid metabolism disorders affect cardiac fibrosis and the role of certain cells in this process. The research uses human heart samples and mouse models, including a specific type of genetically modified mouse with induced hypertension. The study reveals that lipid metabolism disorders significantly contribute to cardiac fibrosis by promoting the transformation of CD34+ cells into FABP4+ fibroblasts, worsening heart fibrosis. The findings suggest potential new treatments for cardiac fibrosis. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.","PeriodicalId":50466,"journal":{"name":"Experimental and Molecular Medicine","volume":"56 8","pages":"1869-1886"},"PeriodicalIF":9.5,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s12276-024-01309-9.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142094130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical application of whole-genome sequencing of solid tumors for precision oncology 实体瘤全基因组测序在精准肿瘤学中的临床应用。
IF 9.5 2区 医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-08-13 DOI: 10.1038/s12276-024-01288-x
Ryul Kim, Seokhwi Kim, Brian Baek-Lok Oh, Woo Sik Yu, Chang Woo Kim, Hoon Hur, Sang-Yong Son, Min Jae Yang, Dae Sung Cho, Taeyang Ha, Subin Heo, Jeon Yeob Jang, Jae Sung Yun, Kyu-Sung Kwack, Jai Keun Kim, Jimi Huh, Sun Gyo Lim, Sang-Uk Han, Hyun Woo Lee, Ji Eun Park, Chul-Ho Kim, Jin Roh, Young Wha Koh, Dakeun Lee, Jang-Hee Kim, Gil Ho Lee, Choong-Kyun Noh, Yun Jung Jung, Ji Won Park, Seungsoo Sheen, Mi Sun Ahn, Yong Won Choi, Tae-Hwan Kim, Seok Yun Kang, Jin-Hyuk Choi, Soo Yeon Baek, Kee Myung Lee, Sun Il Kim, Sung Hyun Noh, Se-Hyuk Kim, Hyemin Hwang, Eunjung Joo, Shinjung Lee, Jong-Yeon Shin, Ji-Young Yun, Junggil Park, Kijong Yi, Youngoh Kwon, Won-Chul Lee, Hansol Park, Joonoh Lim, Boram Yi, Jaemo Koo, June-Young Koh, Sangmoon Lee, Yuna Lee, Bo-Rahm Lee, Erin Connolly-Strong, Young Seok Ju, Minsuk Kwon
Genomic alterations in tumors play a pivotal role in determining their clinical trajectory and responsiveness to treatment. Targeted panel sequencing (TPS) has served as a key clinical tool over the past decade, but advancements in sequencing costs and bioinformatics have now made whole-genome sequencing (WGS) a feasible single-assay approach for almost all cancer genomes in clinical settings. This paper reports on the findings of a prospective, single-center study exploring the real-world clinical utility of WGS (tumor and matched normal tissues) and has two primary objectives: (1) assessing actionability for therapeutic options and (2) providing clarity for clinical questions. Of the 120 patients with various solid cancers who were enrolled, 95 (79%) successfully received genomic reports within a median of 11 working days from sampling to reporting. Analysis of these 95 WGS reports revealed that 72% (68/95) yielded clinically relevant insights, with 69% (55/79) pertaining to therapeutic actionability and 81% (13/16) pertaining to clinical clarity. These benefits include the selection of informed therapeutics and/or active clinical trials based on the identification of driver mutations, tumor mutational burden (TMB) and mutational signatures, pathogenic germline variants that warrant genetic counseling, and information helpful for inferring cancer origin. Our findings highlight the potential of WGS as a comprehensive tool in precision oncology and suggests that it should be integrated into routine clinical practice to provide a complete image of the genomic landscape to enable tailored cancer management. Personalized medicine customizes cancer treatment to each patient, using molecular profiling of tumors to find specific genetic changes that can guide treatment. Despite progress, the practical use of whole-genome sequencing in clinical settings is still not fully explored. This study examines the use of WGS for cancer patients, aiming to make it a regular part of care. The study involved 120 participants with various solid tumors, using the CancerVisionTM for sequencing. Researchers conclude that WGS is a valuable tool in precision oncology, offering insights that can significantly impact treatment strategies. The study marks progress in integration of genomic medicine into clinical practice, showcasing the feasibility and benefits of WGS in a real-world hospital setting. Future research may further establish WGS as a standard part of cancer care, potentially changing how we approach treatment for different tumor types. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.
肿瘤的基因组改变在决定肿瘤的临床轨迹和对治疗的反应性方面起着关键作用。在过去十年中,靶向基因组测序(TPS)已成为一种重要的临床工具,但测序成本和生物信息学的进步已使全基因组测序(WGS)成为一种可行的单一检测方法,可用于临床环境中几乎所有癌症基因组的检测。本文报告了一项探索 WGS(肿瘤和匹配的正常组织)实际临床效用的前瞻性单中心研究的结果,该研究有两个主要目标:(1) 评估治疗方案的可操作性;(2) 阐明临床问题。在入组的 120 名各种实体癌患者中,有 95 人(79%)在从取样到报告的中位数 11 个工作日内成功收到了基因组报告。对这 95 份 WGS 报告的分析表明,72%(68/95)的报告具有临床相关性,其中 69%(55/79)与治疗可操作性有关,81%(13/16)与临床清晰度有关。这些益处包括:根据驱动突变、肿瘤突变负荷 (TMB) 和突变特征、需要进行遗传咨询的致病性种系变异以及有助于推断癌症起源的信息的鉴定,选择明智的治疗方法和/或进行积极的临床试验。我们的研究结果凸显了 WGS 作为精准肿瘤学综合工具的潜力,并建议将其纳入常规临床实践,以提供完整的基因组图谱,从而实现量身定制的癌症管理。
{"title":"Clinical application of whole-genome sequencing of solid tumors for precision oncology","authors":"Ryul Kim, Seokhwi Kim, Brian Baek-Lok Oh, Woo Sik Yu, Chang Woo Kim, Hoon Hur, Sang-Yong Son, Min Jae Yang, Dae Sung Cho, Taeyang Ha, Subin Heo, Jeon Yeob Jang, Jae Sung Yun, Kyu-Sung Kwack, Jai Keun Kim, Jimi Huh, Sun Gyo Lim, Sang-Uk Han, Hyun Woo Lee, Ji Eun Park, Chul-Ho Kim, Jin Roh, Young Wha Koh, Dakeun Lee, Jang-Hee Kim, Gil Ho Lee, Choong-Kyun Noh, Yun Jung Jung, Ji Won Park, Seungsoo Sheen, Mi Sun Ahn, Yong Won Choi, Tae-Hwan Kim, Seok Yun Kang, Jin-Hyuk Choi, Soo Yeon Baek, Kee Myung Lee, Sun Il Kim, Sung Hyun Noh, Se-Hyuk Kim, Hyemin Hwang, Eunjung Joo, Shinjung Lee, Jong-Yeon Shin, Ji-Young Yun, Junggil Park, Kijong Yi, Youngoh Kwon, Won-Chul Lee, Hansol Park, Joonoh Lim, Boram Yi, Jaemo Koo, June-Young Koh, Sangmoon Lee, Yuna Lee, Bo-Rahm Lee, Erin Connolly-Strong, Young Seok Ju, Minsuk Kwon","doi":"10.1038/s12276-024-01288-x","DOIUrl":"10.1038/s12276-024-01288-x","url":null,"abstract":"Genomic alterations in tumors play a pivotal role in determining their clinical trajectory and responsiveness to treatment. Targeted panel sequencing (TPS) has served as a key clinical tool over the past decade, but advancements in sequencing costs and bioinformatics have now made whole-genome sequencing (WGS) a feasible single-assay approach for almost all cancer genomes in clinical settings. This paper reports on the findings of a prospective, single-center study exploring the real-world clinical utility of WGS (tumor and matched normal tissues) and has two primary objectives: (1) assessing actionability for therapeutic options and (2) providing clarity for clinical questions. Of the 120 patients with various solid cancers who were enrolled, 95 (79%) successfully received genomic reports within a median of 11 working days from sampling to reporting. Analysis of these 95 WGS reports revealed that 72% (68/95) yielded clinically relevant insights, with 69% (55/79) pertaining to therapeutic actionability and 81% (13/16) pertaining to clinical clarity. These benefits include the selection of informed therapeutics and/or active clinical trials based on the identification of driver mutations, tumor mutational burden (TMB) and mutational signatures, pathogenic germline variants that warrant genetic counseling, and information helpful for inferring cancer origin. Our findings highlight the potential of WGS as a comprehensive tool in precision oncology and suggests that it should be integrated into routine clinical practice to provide a complete image of the genomic landscape to enable tailored cancer management. Personalized medicine customizes cancer treatment to each patient, using molecular profiling of tumors to find specific genetic changes that can guide treatment. Despite progress, the practical use of whole-genome sequencing in clinical settings is still not fully explored. This study examines the use of WGS for cancer patients, aiming to make it a regular part of care. The study involved 120 participants with various solid tumors, using the CancerVisionTM for sequencing. Researchers conclude that WGS is a valuable tool in precision oncology, offering insights that can significantly impact treatment strategies. The study marks progress in integration of genomic medicine into clinical practice, showcasing the feasibility and benefits of WGS in a real-world hospital setting. Future research may further establish WGS as a standard part of cancer care, potentially changing how we approach treatment for different tumor types. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.","PeriodicalId":50466,"journal":{"name":"Experimental and Molecular Medicine","volume":"56 8","pages":"1856-1868"},"PeriodicalIF":9.5,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s12276-024-01288-x.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141977070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Foxo1-YAP-Notch1 axis reprograms STING-mediated innate immunity in NASH progression Foxo1-YAP-Notch1轴重新规划了STING介导的先天性免疫在NASH进展中的作用。
IF 9.5 2区 医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-08-09 DOI: 10.1038/s12276-024-01280-5
Dongwei Xu, Xiaoye Qu, Tao Yang, Mingwei Sheng, Xiyun Bian, Yongqiang Zhan, Yizhu Tian, Yuanbang Lin, Yuting Jin, Xiao Wang, Michael Ke, Longfeng Jiang, Changyong Li, Qiang Xia, Douglas G. Farmer, Bibo Ke
Innate immune activation is critical for initiating hepatic inflammation during nonalcoholic steatohepatitis (NASH) progression. However, the mechanisms by which immunoregulatory molecules recognize lipogenic, fibrotic, and inflammatory signals remain unclear. Here, we show that high-fat diet (HFD)-induced oxidative stress activates Foxo1, YAP, and Notch1 signaling in hepatic macrophages. Macrophage Foxo1 deficiency (Foxo1M-KO) ameliorated hepatic inflammation, steatosis, and fibrosis, with reduced STING, TBK1, and NF-κB activation in HFD-challenged livers. However, Foxo1 and YAP double knockout (Foxo1/YAPM-DKO) or Foxo1 and Notch1 double knockout (Foxo1/Notch1M-DKO) promoted STING function and exacerbated HFD-induced liver injury. Interestingly, Foxo1M-KO strongly reduced TGF-β1 release from palmitic acid (PA)- and oleic acid (OA)-stimulated Kupffer cells and decreased Col1α1, CCL2, and Timp1 expression but increased MMP1 expression in primary hepatic stellate cells (HSCs) after coculture with Kupffer cells. Notably, PA and OA challenge in Kupffer cells augmented LIMD1 and LATS1 colocalization and interaction, which induced YAP nuclear translocation. Foxo1M-KO activated PGC-1α and increased nuclear YAP activity, modulating mitochondrial biogenesis. Using chromatin immunoprecipitation (ChIP) coupled with massively parallel sequencing (ChIP-Seq) and in situ RNA hybridization, we found that NICD colocalizes with YAP and targets Mb21d1 (cGAS), while YAP functions as a novel coactivator of the NICD, which is crucial for reprogramming STING function in NASH progression. These findings highlight the importance of the macrophage Foxo1–YAP–Notch1 axis as a key molecular regulator that controls lipid metabolism, inflammation, and innate immunity in NASH. In the battle against nonalcoholic steatohepatitis, it’s vital to understand how our immune system contributes to liver harm. Researchers found that a protein named STING is crucial in liver inflammation and damage as it identifies damaged DNA. They investigate how certain proteins and processes in immune cells affect STING’s function and NASH’s progression. Researchers discovered that decreasing the activity of a protein named Foxo1 in macrophagesresults in less liver damage and inflammation in mice on a high-fat diet. They also examined how other signaling processes, like the Hippo–YAP and Notch1 processes, interact with STING and contribute to the disease. Their findings indicate that adjusting these processes can reduce liver damage, steatosis, and inflammation, suggesting new potential treatment targets for NASH, potentially improving the lives of those affected by this condition.This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.
在非酒精性脂肪性肝炎(NASH)发展过程中,先天性免疫激活是引发肝脏炎症的关键。然而,免疫调节分子识别致脂、纤维化和炎症信号的机制仍不清楚。在这里,我们发现高脂饮食(HFD)诱导的氧化应激激活了肝巨噬细胞中的 Foxo1、YAP 和 Notch1 信号传导。巨噬细胞 Foxo1 缺乏症(Foxo1M-KO)可改善肝脏炎症、脂肪变性和纤维化,同时减少 STING、TBK1 和 NF-κB 在高脂饮食挑战肝脏中的激活。然而,Foxo1和YAP双基因敲除(Foxo1/YAPM-DKO)或Foxo1和Notch1双基因敲除(Foxo1/Notch1M-DKO)可促进STING功能,并加剧高频分解诱导的肝损伤。有趣的是,Foxo1M-KO强烈减少了棕榈酸(PA)和油酸(OA)刺激的Kupffer细胞中TGF-β1的释放,并降低了Col1α1、CCL2和Timp1的表达,但增加了与Kupffer细胞共培养后原代肝星状细胞(HSCs)中MMP1的表达。值得注意的是,Kupffer 细胞中的 PA 和 OA 挑战增强了 LIMD1 和 LATS1 的共定位和相互作用,从而诱导了 YAP 的核转位。Foxo1M-KO 激活了 PGC-1α,增加了 YAP 核活性,从而调节了线粒体的生物生成。利用染色质免疫共沉淀(ChIP)结合大规模平行测序(ChIP-Seq)和原位 RNA 杂交,我们发现 NICD 与 YAP 共定位并靶向 Mb21d1 (cGAS),而 YAP 作为 NICD 的新型辅助激活剂,在 NASH 进展过程中对 STING 功能的重编程至关重要。这些发现凸显了巨噬细胞Foxo1-YAP-Notch1轴作为控制NASH中脂质代谢、炎症和先天免疫的关键分子调控因子的重要性。
{"title":"The Foxo1-YAP-Notch1 axis reprograms STING-mediated innate immunity in NASH progression","authors":"Dongwei Xu, Xiaoye Qu, Tao Yang, Mingwei Sheng, Xiyun Bian, Yongqiang Zhan, Yizhu Tian, Yuanbang Lin, Yuting Jin, Xiao Wang, Michael Ke, Longfeng Jiang, Changyong Li, Qiang Xia, Douglas G. Farmer, Bibo Ke","doi":"10.1038/s12276-024-01280-5","DOIUrl":"10.1038/s12276-024-01280-5","url":null,"abstract":"Innate immune activation is critical for initiating hepatic inflammation during nonalcoholic steatohepatitis (NASH) progression. However, the mechanisms by which immunoregulatory molecules recognize lipogenic, fibrotic, and inflammatory signals remain unclear. Here, we show that high-fat diet (HFD)-induced oxidative stress activates Foxo1, YAP, and Notch1 signaling in hepatic macrophages. Macrophage Foxo1 deficiency (Foxo1M-KO) ameliorated hepatic inflammation, steatosis, and fibrosis, with reduced STING, TBK1, and NF-κB activation in HFD-challenged livers. However, Foxo1 and YAP double knockout (Foxo1/YAPM-DKO) or Foxo1 and Notch1 double knockout (Foxo1/Notch1M-DKO) promoted STING function and exacerbated HFD-induced liver injury. Interestingly, Foxo1M-KO strongly reduced TGF-β1 release from palmitic acid (PA)- and oleic acid (OA)-stimulated Kupffer cells and decreased Col1α1, CCL2, and Timp1 expression but increased MMP1 expression in primary hepatic stellate cells (HSCs) after coculture with Kupffer cells. Notably, PA and OA challenge in Kupffer cells augmented LIMD1 and LATS1 colocalization and interaction, which induced YAP nuclear translocation. Foxo1M-KO activated PGC-1α and increased nuclear YAP activity, modulating mitochondrial biogenesis. Using chromatin immunoprecipitation (ChIP) coupled with massively parallel sequencing (ChIP-Seq) and in situ RNA hybridization, we found that NICD colocalizes with YAP and targets Mb21d1 (cGAS), while YAP functions as a novel coactivator of the NICD, which is crucial for reprogramming STING function in NASH progression. These findings highlight the importance of the macrophage Foxo1–YAP–Notch1 axis as a key molecular regulator that controls lipid metabolism, inflammation, and innate immunity in NASH. In the battle against nonalcoholic steatohepatitis, it’s vital to understand how our immune system contributes to liver harm. Researchers found that a protein named STING is crucial in liver inflammation and damage as it identifies damaged DNA. They investigate how certain proteins and processes in immune cells affect STING’s function and NASH’s progression. Researchers discovered that decreasing the activity of a protein named Foxo1 in macrophagesresults in less liver damage and inflammation in mice on a high-fat diet. They also examined how other signaling processes, like the Hippo–YAP and Notch1 processes, interact with STING and contribute to the disease. Their findings indicate that adjusting these processes can reduce liver damage, steatosis, and inflammation, suggesting new potential treatment targets for NASH, potentially improving the lives of those affected by this condition.This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.","PeriodicalId":50466,"journal":{"name":"Experimental and Molecular Medicine","volume":"56 8","pages":"1843-1855"},"PeriodicalIF":9.5,"publicationDate":"2024-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s12276-024-01280-5.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141914428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SMC3 contributes to heart development by regulating super-enhancer associated genes SMC3 通过调节超级增强子相关基因促进心脏发育。
IF 9.5 2区 医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-08-01 DOI: 10.1038/s12276-024-01293-0
Bowen Zhang, Yongchang Zhu, Zhen Zhang, Feizhen Wu, Xiaojing Ma, Wei Sheng, Ranran Dai, Zhenglong Guo, Weili Yan, Lili Hao, Guoying Huang, Duan Ma, Bingtao Hao, Jing Ma
Abnormal cardiac development has been observed in individuals with Cornelia de Lange syndrome (CdLS) due to mutations in genes encoding members of the cohesin complex. However, the precise role of cohesin in heart development remains elusive. In this study, we aimed to elucidate the indispensable role of SMC3, a component of the cohesin complex, in cardiac development and its underlying mechanism. Our investigation revealed that CdLS patients with SMC3 mutations have high rates of congenital heart disease (CHD). We utilized heart-specific Smc3-knockout (SMC3-cKO) mice, which exhibit varying degrees of outflow tract (OFT) abnormalities, to further explore this relationship. Additionally, we identified 16 rare SMC3 variants with potential pathogenicity in individuals with isolated CHD. By employing single-nucleus RNA sequencing and chromosome conformation capture high-throughput genome-wide translocation sequencing, we revealed that Smc3 deletion downregulates the expression of key genes, including Ets2, in OFT cardiac muscle cells by specifically decreasing interactions between super-enhancers (SEs) and promoters. Notably, Ets2-SE-null mice also exhibit delayed OFT development in the heart. Our research revealed a novel role for SMC3 in heart development via the regulation of SE-associated genes, suggesting its potential relevance as a CHD-related gene and providing crucial insights into the molecular basis of cardiac development. Understanding heart development is vital as defects in this process are a major cause of birth abnormalities. This study focuses on a protein, SMC3, and its role in heart development. Experiments were conducted on mice genetically altered to lack SMC3 in heart cells. Researchers found that mice without SMC3 had various heart defects, like those seen in humans with congenital heart disease. They also found mutations in the SMC3 gene in patients with congenital heart disease, suggesting a link between SMC3 and heart development in humans. The findings reveal that SMC3 plays a crucial role in heart development, with its absence leading to significant heart defects in mice. These results suggest a potential genetic cause for some forms of congenital heart disease in humans. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author. Introduction
科尼莉亚-德-朗格综合征(CdLS)患者的心脏发育异常是由于编码凝聚素复合体成员的基因发生突变所致。然而,凝聚素在心脏发育过程中的确切作用仍然难以捉摸。在本研究中,我们旨在阐明凝聚素复合体的一个成分 SMC3 在心脏发育中不可或缺的作用及其内在机制。我们的调查发现,SMC3突变的CdLS患者患有先天性心脏病(CHD)的比例很高。我们利用表现出不同程度流出道(OFT)异常的心脏特异性 Smc3 基因敲除(SMC3-cKO)小鼠来进一步探讨这种关系。此外,我们还发现了 16 个罕见的 SMC3 变体,这些变体在孤立性先天性心脏病患者中具有潜在的致病性。通过采用单核 RNA 测序和染色体构象捕获高通量全基因组易位测序,我们发现 Smc3 缺失会通过特异性减少超级增强子(SE)和启动子之间的相互作用,下调包括 Ets2 在内的关键基因在 OFT 心肌细胞中的表达。值得注意的是,Ets2-SE缺失小鼠也表现出心脏OFT发育延迟。我们的研究揭示了SMC3通过调控SE相关基因在心脏发育过程中的新作用,表明其作为CHD相关基因的潜在相关性,并为了解心脏发育的分子基础提供了重要信息。
{"title":"SMC3 contributes to heart development by regulating super-enhancer associated genes","authors":"Bowen Zhang, Yongchang Zhu, Zhen Zhang, Feizhen Wu, Xiaojing Ma, Wei Sheng, Ranran Dai, Zhenglong Guo, Weili Yan, Lili Hao, Guoying Huang, Duan Ma, Bingtao Hao, Jing Ma","doi":"10.1038/s12276-024-01293-0","DOIUrl":"10.1038/s12276-024-01293-0","url":null,"abstract":"Abnormal cardiac development has been observed in individuals with Cornelia de Lange syndrome (CdLS) due to mutations in genes encoding members of the cohesin complex. However, the precise role of cohesin in heart development remains elusive. In this study, we aimed to elucidate the indispensable role of SMC3, a component of the cohesin complex, in cardiac development and its underlying mechanism. Our investigation revealed that CdLS patients with SMC3 mutations have high rates of congenital heart disease (CHD). We utilized heart-specific Smc3-knockout (SMC3-cKO) mice, which exhibit varying degrees of outflow tract (OFT) abnormalities, to further explore this relationship. Additionally, we identified 16 rare SMC3 variants with potential pathogenicity in individuals with isolated CHD. By employing single-nucleus RNA sequencing and chromosome conformation capture high-throughput genome-wide translocation sequencing, we revealed that Smc3 deletion downregulates the expression of key genes, including Ets2, in OFT cardiac muscle cells by specifically decreasing interactions between super-enhancers (SEs) and promoters. Notably, Ets2-SE-null mice also exhibit delayed OFT development in the heart. Our research revealed a novel role for SMC3 in heart development via the regulation of SE-associated genes, suggesting its potential relevance as a CHD-related gene and providing crucial insights into the molecular basis of cardiac development. Understanding heart development is vital as defects in this process are a major cause of birth abnormalities. This study focuses on a protein, SMC3, and its role in heart development. Experiments were conducted on mice genetically altered to lack SMC3 in heart cells. Researchers found that mice without SMC3 had various heart defects, like those seen in humans with congenital heart disease. They also found mutations in the SMC3 gene in patients with congenital heart disease, suggesting a link between SMC3 and heart development in humans. The findings reveal that SMC3 plays a crucial role in heart development, with its absence leading to significant heart defects in mice. These results suggest a potential genetic cause for some forms of congenital heart disease in humans. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author. Introduction","PeriodicalId":50466,"journal":{"name":"Experimental and Molecular Medicine","volume":"56 8","pages":"1826-1842"},"PeriodicalIF":9.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s12276-024-01293-0.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141861489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inhibition of BCAT1-mediated cytosolic leucine metabolism regulates Th17 responses via the mTORC1-HIF1α pathway 抑制 BCAT1 介导的细胞膜亮氨酸代谢可通过 mTORC1-HIF1α 途径调节 Th17 反应。
IF 9.5 2区 医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-08-01 DOI: 10.1038/s12276-024-01286-z
Yeon Jun Kang, Woorim Song, Su Jeong Lee, Seung Ah Choi, Sihyun Chae, Bo Ruem Yoon, Hee Young Kim, Jung Ho Lee, Chulwoo Kim, Joo-Youn Cho, Hyun Je Kim, Won-Woo Lee
Branched-chain amino acids (BCAAs), particularly leucine, are indispensable AAs for immune regulation through metabolic rewiring. However, the molecular mechanism underlying this phenomenon remains unclear. Our investigation revealed that T-cell receptor (TCR)-activated human CD4+ T cells increase the expression of BCAT1, a cytosolic enzyme responsible for BCAA catabolism, and SLC7A5, a major BCAA transporter. This upregulation facilitates increased leucine influx and catabolism, which are particularly crucial for Th17 responses. Activated CD4+ T cells induce an alternative pathway of cytosolic leucine catabolism, generating a pivotal metabolite, β-hydroxy β-methylbutyric acid (HMB), by acting on BCAT1 and 4-hydroxyphenylpyruvate dioxygenase (HPD)/HPD-like protein (HPDL). Inhibition of BCAT1-mediated cytosolic leucine metabolism, either with BCAT1 inhibitor 2 (Bi2) or through BCAT1, HPD, or HPDL silencing using shRNA, attenuates IL-17 production, whereas HMB supplementation abrogates this effect. Mechanistically, HMB contributes to the regulation of the mTORC1-HIF1α pathway, a major signaling pathway for IL-17 production, by increasing the mRNA expression of HIF1α. This finding was corroborated by the observation that treatment with L-β-homoleucine (LβhL), a leucine analog and competitive inhibitor of BCAT1, decreased IL-17 production by TCR-activated CD4+ T cells. In an in vivo experimental autoimmune encephalomyelitis (EAE) model, blockade of BCAT1-mediated leucine catabolism, either through a BCAT1 inhibitor or LβhL treatment, mitigated EAE severity by decreasing HIF1α expression and IL-17 production in spinal cord mononuclear cells. Our findings elucidate the role of BCAT1-mediated cytoplasmic leucine catabolism in modulating IL-17 production via HMB-mediated regulation of mTORC1-HIF1α, providing insights into its relevance to inflammatory conditions. T-cell, a type of infection-fighting white blood cell, alter their metabolic process, relying heavily on amino acids, the building blocks of proteins. This study investigates how T cells use the amino acid leucine to power their response. Researchers conducted experiments with human T-cell and a mouse model of autoimmune disease, a condition where the body attacks its own cells. They studied how leucine’s metabolic process affects T-cell function. The study discovered that a specific process involving leucine’s metabolic pathway in T cells is vital for their ability to produce IL-17. Blocking a crucial enzyme reduced IL-17 production and eased symptoms in a mouse model of autoimmune disease. These findings underline the importance of leucine’s metabolic process in T-cell function and suggest a potential target for treating autoimmune diseases more effectively, offering hope for new treatments. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.
支链氨基酸(BCAAs),尤其是亮氨酸,是通过新陈代谢重新布线进行免疫调节的不可或缺的氨基酸。然而,这一现象的分子机制仍不清楚。我们的研究发现,T 细胞受体(TCR)激活的人类 CD4+ T 细胞会增加 BCAT1(一种负责 BCAA 分解代谢的细胞膜酶)和 SLC7A5(一种主要的 BCAA 转运体)的表达。这种上调促进了亮氨酸流入和分解的增加,这对 Th17 反应尤为重要。活化的 CD4+ T 细胞通过作用于 BCAT1 和 4-hydroxyphenylpyruvate dioxygenase (HPD)/HPD-like protein (HPDL),诱导细胞膜亮氨酸分解代谢的替代途径,产生一种关键的代谢产物--β-羟基 β-甲基丁酸 (HMB)。使用 BCAT1 抑制剂 2(Bi2)或使用 shRNA 抑制 BCAT1、HPD 或 HPDL 可抑制 BCAT1 介导的细胞质亮氨酸代谢,从而减少 IL-17 的产生,而补充 HMB 则可消除这种影响。从机理上讲,HMB通过增加HIF1α的mRNA表达,有助于调节mTORC1-HIF1α通路(IL-17产生的主要信号通路)。用亮氨酸类似物和 BCAT1 竞争性抑制剂 L-β-高亮氨酸(LβhL)处理 TCR 激活的 CD4+ T 细胞,可减少 IL-17 的产生,这一观察结果证实了上述发现。在活体实验性自身免疫性脑脊髓炎(EAE)模型中,通过 BCAT1 抑制剂或 LβhL 处理阻断 BCAT1 介导的亮氨酸分解,可降低脊髓单核细胞中 HIF1α 的表达和 IL-17 的产生,从而减轻 EAE 的严重程度。我们的研究结果阐明了 BCAT1 介导的细胞质亮氨酸分解代谢在通过 HMB 介导的 mTORC1-HIF1α 调节 IL-17 生成过程中的作用,为其与炎症条件的相关性提供了见解。
{"title":"Inhibition of BCAT1-mediated cytosolic leucine metabolism regulates Th17 responses via the mTORC1-HIF1α pathway","authors":"Yeon Jun Kang, Woorim Song, Su Jeong Lee, Seung Ah Choi, Sihyun Chae, Bo Ruem Yoon, Hee Young Kim, Jung Ho Lee, Chulwoo Kim, Joo-Youn Cho, Hyun Je Kim, Won-Woo Lee","doi":"10.1038/s12276-024-01286-z","DOIUrl":"10.1038/s12276-024-01286-z","url":null,"abstract":"Branched-chain amino acids (BCAAs), particularly leucine, are indispensable AAs for immune regulation through metabolic rewiring. However, the molecular mechanism underlying this phenomenon remains unclear. Our investigation revealed that T-cell receptor (TCR)-activated human CD4+ T cells increase the expression of BCAT1, a cytosolic enzyme responsible for BCAA catabolism, and SLC7A5, a major BCAA transporter. This upregulation facilitates increased leucine influx and catabolism, which are particularly crucial for Th17 responses. Activated CD4+ T cells induce an alternative pathway of cytosolic leucine catabolism, generating a pivotal metabolite, β-hydroxy β-methylbutyric acid (HMB), by acting on BCAT1 and 4-hydroxyphenylpyruvate dioxygenase (HPD)/HPD-like protein (HPDL). Inhibition of BCAT1-mediated cytosolic leucine metabolism, either with BCAT1 inhibitor 2 (Bi2) or through BCAT1, HPD, or HPDL silencing using shRNA, attenuates IL-17 production, whereas HMB supplementation abrogates this effect. Mechanistically, HMB contributes to the regulation of the mTORC1-HIF1α pathway, a major signaling pathway for IL-17 production, by increasing the mRNA expression of HIF1α. This finding was corroborated by the observation that treatment with L-β-homoleucine (LβhL), a leucine analog and competitive inhibitor of BCAT1, decreased IL-17 production by TCR-activated CD4+ T cells. In an in vivo experimental autoimmune encephalomyelitis (EAE) model, blockade of BCAT1-mediated leucine catabolism, either through a BCAT1 inhibitor or LβhL treatment, mitigated EAE severity by decreasing HIF1α expression and IL-17 production in spinal cord mononuclear cells. Our findings elucidate the role of BCAT1-mediated cytoplasmic leucine catabolism in modulating IL-17 production via HMB-mediated regulation of mTORC1-HIF1α, providing insights into its relevance to inflammatory conditions. T-cell, a type of infection-fighting white blood cell, alter their metabolic process, relying heavily on amino acids, the building blocks of proteins. This study investigates how T cells use the amino acid leucine to power their response. Researchers conducted experiments with human T-cell and a mouse model of autoimmune disease, a condition where the body attacks its own cells. They studied how leucine’s metabolic process affects T-cell function. The study discovered that a specific process involving leucine’s metabolic pathway in T cells is vital for their ability to produce IL-17. Blocking a crucial enzyme reduced IL-17 production and eased symptoms in a mouse model of autoimmune disease. These findings underline the importance of leucine’s metabolic process in T-cell function and suggest a potential target for treating autoimmune diseases more effectively, offering hope for new treatments. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.","PeriodicalId":50466,"journal":{"name":"Experimental and Molecular Medicine","volume":"56 8","pages":"1776-1790"},"PeriodicalIF":9.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s12276-024-01286-z.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141861486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comprehensive molecular characterization of TFE3-rearranged renal cell carcinoma TFE3重排肾细胞癌的综合分子特征。
IF 9.5 2区 医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-08-01 DOI: 10.1038/s12276-024-01291-2
Cho-Rong Lee, Jungyo Suh, Dongjun Jang, Bo-Yeong Jin, Jaeso Cho, Moses Lee, Hyungtai Sim, Minyong Kang, Jueun Lee, Ju Hyun Park, Kyoung-Hwa Lee, Geum-Sook Hwang, Kyung Chul Moon, Cheryn Song, Ja Hyeon Ku, Cheol Kwak, Hyeon Hoe Kim, Sung-Yup Cho, Murim Choi, Chang Wook Jeong
TFE3-rearranged renal cell cancer (tRCC) is a rare form of RCC that involves chromosomal translocation of the Xp11.2 TFE3 gene. Despite its early onset and poor prognosis, the molecular mechanisms of the pathogenesis of tRCC remain elusive. This study aimed to identify novel therapeutic targets for patients with primary and recurrent tRCC. We collected 19 TFE3-positive RCC tissues that were diagnosed by immunohistochemistry and subjected them to genetic characterization to examine their genomic and transcriptomic features. Tumor-specific signatures were extracted using whole exome sequencing (WES) and RNA sequencing (RNA-seq) data, and the functional consequences were analyzed in a cell line with TFE3 translocation. Both a low burden of somatic single nucleotide variants (SNVs) and a positive correlation between the number of somatic variants and age of onset were observed. Transcriptome analysis revealed that four samples (21.1%) lacked the expected fusion event and clustered with the genomic profiles of clear cell RCC (ccRCC) tissues. The fusion event also demonstrated an enrichment of upregulated genes associated with mitochondrial respiration compared with ccRCC expression profiles. Comparison of the RNA expression profile with the TFE3 ChIP-seq pattern data indicated that PPARGC1A is a metabolic regulator of the oncogenic process. Cell proliferation was reduced when PPARGC1A and its related metabolic pathways were repressed by its inhibitor SR-18292. In conclusion, we demonstrate that PPARGC1A-mediated mitochondrial respiration can be considered a potential therapeutic target in tRCC. This study identifies an uncharacterized genetic profile of an RCC subtype with unique clinical features and provides therapeutic options specific to tRCC. Understanding the unique traits of a rare kidney cancer type, TFE3-rearranged renal cell carcinoma, is important due to its poor response to usual treatments. This study explores the genetic and metabolic makeup of tRCC, comparing it with clear cell RCC and normal kidney cells. Using a mix of cell culture, whole exome sequencing, and various molecular analyses, the team conducted an experiment to reveal the unique genetic and metabolic profiles of tRCC. The researchers conclude that targeting the metabolic changes in tRCC, specifically through inhibiting PPARGC1A-mediated mitochondrial respiration, offers a new treatment approach. This approach marks a significant step in understanding and potentially treating tRCC. The implications of this study could lead to more effective treatments for patients with this challenging cancer type, emphasizing the importance of metabolic pathways in cancer therapy. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.
TFE3重排肾细胞癌(tRCC)是一种罕见的肾细胞癌,涉及Xp11.2 TFE3基因的染色体易位。尽管tRCC发病早、预后差,但其发病的分子机制仍然难以捉摸。本研究旨在为原发性和复发性 tRCC 患者确定新的治疗靶点。我们收集了19个经免疫组化确诊的TFE3阳性RCC组织,并对它们进行了基因鉴定,以检查它们的基因组和转录组特征。利用全外显子组测序(WES)和RNA测序(RNA-seq)数据提取了肿瘤特异性特征,并在TFE3易位的细胞系中分析了其功能性后果。结果发现,体细胞单核苷酸变异(SNV)的负担较低,体细胞变异的数量与发病年龄呈正相关。转录组分析表明,有四个样本(21.1%)缺乏预期的融合事件,并与透明细胞RCC(ccRCC)组织的基因组图谱聚集在一起。与ccRCC的表达图谱相比,融合事件还显示出与线粒体呼吸相关的基因富集上调。RNA 表达谱与 TFE3 ChIP-seq 模式数据的比较表明,PPARGC1A 是致癌过程的代谢调节因子。当 PPARGC1A 及其相关代谢通路被其抑制剂 SR-18292 抑制时,细胞增殖会减少。总之,我们证明 PPARGC1A 介导的线粒体呼吸可被视为 tRCC 的潜在治疗靶点。这项研究确定了一种具有独特临床特征的 RCC 亚型的未定性遗传特征,并提供了针对 tRCC 的治疗方案。
{"title":"Comprehensive molecular characterization of TFE3-rearranged renal cell carcinoma","authors":"Cho-Rong Lee, Jungyo Suh, Dongjun Jang, Bo-Yeong Jin, Jaeso Cho, Moses Lee, Hyungtai Sim, Minyong Kang, Jueun Lee, Ju Hyun Park, Kyoung-Hwa Lee, Geum-Sook Hwang, Kyung Chul Moon, Cheryn Song, Ja Hyeon Ku, Cheol Kwak, Hyeon Hoe Kim, Sung-Yup Cho, Murim Choi, Chang Wook Jeong","doi":"10.1038/s12276-024-01291-2","DOIUrl":"10.1038/s12276-024-01291-2","url":null,"abstract":"TFE3-rearranged renal cell cancer (tRCC) is a rare form of RCC that involves chromosomal translocation of the Xp11.2 TFE3 gene. Despite its early onset and poor prognosis, the molecular mechanisms of the pathogenesis of tRCC remain elusive. This study aimed to identify novel therapeutic targets for patients with primary and recurrent tRCC. We collected 19 TFE3-positive RCC tissues that were diagnosed by immunohistochemistry and subjected them to genetic characterization to examine their genomic and transcriptomic features. Tumor-specific signatures were extracted using whole exome sequencing (WES) and RNA sequencing (RNA-seq) data, and the functional consequences were analyzed in a cell line with TFE3 translocation. Both a low burden of somatic single nucleotide variants (SNVs) and a positive correlation between the number of somatic variants and age of onset were observed. Transcriptome analysis revealed that four samples (21.1%) lacked the expected fusion event and clustered with the genomic profiles of clear cell RCC (ccRCC) tissues. The fusion event also demonstrated an enrichment of upregulated genes associated with mitochondrial respiration compared with ccRCC expression profiles. Comparison of the RNA expression profile with the TFE3 ChIP-seq pattern data indicated that PPARGC1A is a metabolic regulator of the oncogenic process. Cell proliferation was reduced when PPARGC1A and its related metabolic pathways were repressed by its inhibitor SR-18292. In conclusion, we demonstrate that PPARGC1A-mediated mitochondrial respiration can be considered a potential therapeutic target in tRCC. This study identifies an uncharacterized genetic profile of an RCC subtype with unique clinical features and provides therapeutic options specific to tRCC. Understanding the unique traits of a rare kidney cancer type, TFE3-rearranged renal cell carcinoma, is important due to its poor response to usual treatments. This study explores the genetic and metabolic makeup of tRCC, comparing it with clear cell RCC and normal kidney cells. Using a mix of cell culture, whole exome sequencing, and various molecular analyses, the team conducted an experiment to reveal the unique genetic and metabolic profiles of tRCC. The researchers conclude that targeting the metabolic changes in tRCC, specifically through inhibiting PPARGC1A-mediated mitochondrial respiration, offers a new treatment approach. This approach marks a significant step in understanding and potentially treating tRCC. The implications of this study could lead to more effective treatments for patients with this challenging cancer type, emphasizing the importance of metabolic pathways in cancer therapy. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.","PeriodicalId":50466,"journal":{"name":"Experimental and Molecular Medicine","volume":"56 8","pages":"1807-1815"},"PeriodicalIF":9.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s12276-024-01291-2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141861485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Experimental and Molecular Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1